Notice2024-25986
Agency Forms Undergoing Paperwork Reduction Act Review
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 8, 2024
Issuing agencies
Health and Human Services DepartmentCenters for Disease Control and Prevention
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 217 (Friday, November 8, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 217 (Friday, November 8, 2024)]
[Notices]
[Pages 88778-88780]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-25986]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-25-24FI]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Centers
for Disease Control and Prevention (CDC) has submitted the information
collection request titled ``Comprehensive Evaluations for the Well-
Integrated Screening and Evaluation for Women Across the Nation Program
(WISEWOMAN), The National Cardiovascular Health Program (The National
CVH Program), and The Innovative Cardiovascular Health Program (The
Innovative CVH Program)'' to the Office of Management and Budget (OMB)
for review and approval. CDC previously published a ``Proposed Data
Collection Submitted for Public Comment and Recommendations'' notice on
5/7/2024 to obtain comments from the public and affected agencies. CDC
did not receive comments related to the previous notice. This notice
serves to allow an additional 30 days for public and affected agency
comments.
CDC will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to <a href="http://www.reginfo.gov/public/do/PRAMain">www.reginfo.gov/public/do/PRAMain</a> Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Comprehensive Evaluations for the Well-Integrated Screening and
Evaluation for Women Across the Nation Program (WISEWOMAN), The
National Cardiovascular Health Program (The National CVH Program), and
The Innovative Cardiovascular Health Program (The Innovative CVH
Program)--New--National Center for Chronic Disease Prevention and
Health Promotion (NCCDPHP), Centers for Disease Control and Prevention
(CDC).
Background and Brief Description
The Centers for Disease Control and Prevention (CDC) Division for
Heart Disease and Stroke Prevention (DHDSP) are submitting this new
three-year information collection request (ICR) for an evaluation of
the three recently launched cooperative agreements: Well-Integrated
Screening of Women Across the Nation (WISEWOMAN), The National
Cardiovascular Health Program (The National CVH Program), and The
Innovative Cardiovascular Health Program (The Innovative CVH Program).
The WISEWOMAN program supports the early detection and treatment of
hypertension in low-income, uninsured, and underinsured participants,
ages 35-64. The National CVH Program implements evidence-based
strategies to manage CVD in populations impacted by the high prevalence
of CVD, exacerbated by health inequities and disparities, social
determinants, such as low incomes, poor health care, and unfair
opportunity structures, emphasizing hypertension and high cholesterol
control among adults aged 18-85. The Innovative CVH Program focuses on
implementing innovative evidence-based strategies assess and address
the disparities and inequities in communities at highest risk, where
there is a particular need for equity-focused health system
interventions to prevent, detect, control, and manage hypertension and
high cholesterol, specifically among populations with a crude
hypertension prevalence rate of 53% or higher at the census tract
level. For two of the cooperative agreements, recipients collaborate
with public health entities, health systems, health care providers,
community leaders, and other partners through Learning Collaboratives
to facilitate sustainable change and improvement in cardiovascular
health outcomes, particularly for those at the highest risk of poorer
health outcomes. These cooperative agreements build upon CDC's previous
work of identify promising CVD prevention and management practices and
funding various organizations, including State and County governments,
American Indian or Alaska Native tribal governments, non-government
organizations, institutions of higher education, to implement evidence-
based strategies in their jurisdictions. Since the cooperative
agreements are a substantial investment of federal funds, it is
important to demonstrate the types of interventions being implemented
and what is being accomplished using these funds through a
comprehensive evaluation.
The comprehensive evaluation of these programs includes process and
outcome evaluations, and a cross-program analysis to assess the unique
contributions of each program towards evidence-based strategies, health
equity advancement, and health system transformation over the five
program
[[Page 88779]]
years. The evaluation aims to describe the implementation of the
programs, assess the extent to which short-term, intermediate, and
long-term outcomes have been met, and estimate the costs involved in
implementing the programs. The comprehensive evaluation is designed to
complement the evaluations already being conducted by program
recipients. The data collection focuses on obtaining qualitative and
cost information at the organizational and community levels about
strategy implementation, facilitators and barriers, and other
contextual information that affects program implementation and
participant outcomes. Data collection activities of the comprehensive
evaluation include qualitative interviews for evaluability assessments,
exploratory assessments, and cost data collected for a cost study.
During the qualitative data collection, semi-structured interviews will
be conducted with recipients, their partnering sites, and Learning
Collaborative members, providing a multifaceted view of the program's
implementation and outcomes. Cost data will be used to estimate the
implementation costs and value of resources invested by program
recipients and their partners. Cost data will be collected through an
excel-based cost inventory tool, key informant interviews, and document
reviews. There are no costs to respondents except their time. Data
collection tools are crafted to ensure relevance and to capture
essential information needed to evaluate the effectiveness and impact
of the program strategies, while minimizing respondent burden.
The findings from the data collection will provide tailored,
action-oriented, and timely recommendations for program improvement
throughout the program period. It will foster documentation and sharing
of lessons learned, contribute to the evidence base, and support
replication and scaling of promising program strategies. Without
collection of evaluative data, CDC will not be able to capture critical
information needed to continuously improve programmatic efforts and
clearly demonstrate the use of federal funds. CDC requests OMB approval
for 484 annual burden hours. There is no cost to respondents other than
their time to participate.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hours)
----------------------------------------------------------------------------------------------------------------
Recipients............................ Evaluability Assessment 24 1 0.5
Nomination
Form_NCHP_ICHP.
Evaluability Assessment 12 1 0.5
Nomination Form_WW.
Eval Assessment CQM 6 1 1.5
Recipient Interview
Guide NCHP_ICHP.
Eval Assessment CQM 3 1 1.5
Recipient Interview
Guide WW.
Eval Assessment TBC 6 1 1.5
Recipient Interview
Guide NCHP_ICHP.
Eval Assessment TBC 3 1 1.5
Recipient Interview
Guide WW.
Eval Assessment CCL 3 1 1.5
Recipient Interview
Guide NCHP_ICHP.
Eval Assessment CCL 3 1 1.5
Recipient Interview
Guide WW.
Ex Assessment CQM 3 1 1.5
Recipient Interview
Guide NCHP_ICHP.
Ex Assessment CQM 2 1 1.5
Recipient Interview
Guide_WW.
Ex Assessment TBC 3 1 1.5
Recipient Interview
Guide NCHP_ICHP.
Ex Assessment TBC 2 1 1.5
Recipient Partner
Interview Guide_WW.
Ex Assessment CCL 3 1 1.5
Recipient Interview
Guide NCHP_ICHP.
Ex Assessment CCL 2 1 1.5
Recipient Interview
Guide_WW.
Cost Study Interview 37 1 1
Guide_Recipient.
Comprehensive Evaluation 37 1 2.5
Resource Use and Cost
Inventory
Tool_Recipient.
Partners.............................. Eval Assessment CQM 6 1 1.5
Partner Interview Guide
NCHP_ICHP.
Eval Assessment CQM 3 1 1.5
Partner Interview Guide
WW.
Eval Assessment TBC 6 1 1.5
Partner Interview Guide
NCHP_ICHP.
Eval Assessment TBC 3 1 1.5
Partner Interview Guide
WW.
Eval Assessment CCL 6 1 1.5
Partner Interview Guide
NCHP_ICHP.
Eval Assessment CCL 3 1 1.5
Partner Interview Guide
WW.
Ex Assessment CQM 3 1 1.5
Partner Interview Guide
NCHP_ICHP.
Ex Assessment CQM 1 1 1.5
Partner Interview
Guide_WW.
Ex Assessment CCL 3 1 1.5
Partner Interview Guide
NCHP_ICHP.
Ex Assessment CCL 1 1 1.5
Partner Interview
Guide_WW.
Ex Assessment TBC 3 1 1.5
Partner Interview Guide
NCHP_ICHP.
Ex Assessment TBC 1 1 1.5
Partner Interview
Guide_WW.
Cost Study Interview 55 1 1
Guide_Partner.
Comprehensive Evaluation 55 1 2.5
Resource Use and Cost
Inventory Tool_Partner.
Learning Collaborative................ Eval Assessment LC 12 1 1
Interview Guide NCHP
ICHP.
Ex Assessment LC 6 1 1
Interview Guide
NCHP_ICHP.
----------------------------------------------------------------------------------------------------------------
[[Page 88780]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-25986 Filed 11-7-24; 8:45 am]
BILLING CODE 4163-18-P
</pre></body>
</html>Indexed from Federal Register on November 8, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.